Prostate cancer is the second most common cancer in men worldwide. Despite medical advances in recent years, this type of ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, ...

Researchers have identified a new role for the enzyme EZH2 in promoting the progression of aggressive, treatment-resistant ...

Prostate cancer is the second most common cancer in men worldwide and remains a significant cause of cancer deaths. In ...

On International Men's Day, the Clinical Trials Arena team investigates three therapies being investigated in prostate cancer ...

A groundbreaking approach slows tumor growth while boosting the immune system’s defense against cancer cells. Prostate cancer ranks as the second most common cancer among men globally. Despite recent ...

Prostate cancer is the second most common cancer in men worldwide. Researchers have investigated a new strategy for the development of treatment options that not only slow tumor growth, but also ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine.

Furthermore, since TGF-β is associated with immune suppression in tumors, inhibiting this pathway could enhance immunotherapy effectiveness, a treatment with limited success against prostate cancer ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, ...